SOURCE: The Bedford Report

The Bedford Report

July 05, 2011 08:16 ET

Medical Supply Makers Look to Emerging Markets to Stimulate Profits

The Bedford Report Provides Stock Research on Radient Pharmaceuticals & Medtronic

NEW YORK, NY--(Marketwire - Jul 5, 2011) - As the economies in emerging markets continue to grow at a rapid pace, healthcare access has become both far more widespread and higher quality. Many companies in the medical supplies sector are looking to these emerging markets as a means to supplement the tepid growth of domestic medical instrument and supply markets. The Bedford Report examines the outlook for companies in the Medical Equipment & Supplies Industry and provides investment research on Radient Pharmaceuticals Corporation (PINKSHEETS: RXPC) and Medtronic, Inc. (NYSE: MDT). Access to the full company reports can be found at:

www.bedfordreport.com/RXPC

www.bedfordreport.com/MDT

Medtronic's new CEO, Omar Ishrak, is from Bangladesh, and is deeply interested in Chinese expansion. As well as providing access to healthcare in China, Ishrak in interested in trying to improve healthcare in India.

Already this year, Medtronic announced the official opening of its new manufacturing facility, Medtronic Singapore Operations (MSO). The facility will enhance the company's manufacturing capabilities to meet the increase in demand for high quality cardiac devices in Asia.

The Bedford Report releases stock reports on the Medical Equipment & Supplies Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Radient Pharmaceuticals has made a heavy push into India over the past year. Dr. Umesh Bhatia, senior advisor for the Onko-Sure for Radient Pharmaceuticals' operations in India recently announced that his group has secured a major new partnership that "should clearly benefit Radient and is expected to impact the company's bottom line." Bharia announced a new joint venture/partnership with Super Religare Laboratories which is the biggest diagnostics lab in India. The lab serves over fifty-thousand doctors in every hospital, in every state in India. Radient's Onko-SureTest Kit is used for the detection and/or monitoring of 14 different types of cancers.

The Bedford Report provides Investment Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact Information